Anatara is developing proprietary bromelain formulations for gastrointestinal health.

Gastrointestinal Reprogramming Product (GaRP)

Introducing GaRP, a microbiome-targeted dietary supplement
Anatara’s GaRP product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders.

Our lead product is being positioned as an adjunct to existing therapies, and it will not be replacing current prescription medications. Over the last 20 years the use of dietary supplements as adjuncts to prescription drugs has increased significantly.

GI disorders affect a significant proportion of the population at some stage of their life. Approximately 50% of IBS and 30-50% of IBD patients seek additional relief of their symptoms through the use of adjunct therapies – this approach is generally precipitated by the high failure rates of current prescription therapies. Increased education and more detailed evaluation of dietary supplements and has led to health-care providers working with patients to develop individualised programs which include dietary supplements in the symptom management for GI disorders.

Developing a dietary supplement provides several regulatory and commercial advantages as it is less expensive than prescription medicines and has a less risky pathway to market, thereby accelerating market entry. Both the public and health care professionals alike understand the term ‘dietary supplement’ and with the right partner, marketing can be aimed at both the public and professionals. Unlike pharmaceuticals, demonstrating superiority to other products is not necessary. Marketing, sales, and medical affairs activities encourage health care professionals to recommend products to their patients. Therefore, finding and selecting the best marketing partner is critical to the success of a product such as GaRP and consequently this has and will continue to be a major focus for Anatara.

The design of GaRP has been enabled by leveraging published research in conjunction with the extensive body of knowledge generated in-house at Anatara. Bromelain is one of the main components of GaRP and therefore forms the basis of its acceptability as an effective dietary supplement.

Anatara has been actively working on the development of the GaRP product and has completed the dose selection of each formulation component. The Company has recently generated in vitro data to support the effectiveness of GaRP in:
• Removing bacteria with pro-inflammatory properties;

• Reducing inflammation by reducing the release of pro-inflammatory cytokines;

• Regenerating the integrity of the gastrointestinal tract; and

• Stimulating mucosal healing.

Further information on the proof of concept results can be found here.

Anatara will commence planning for a human clinical study for IBS with patient recruitment anticipated to start in the second half of 2019.

In parallel Anatara will move GaRP into the final stage of pre-clinical development for IBD with mouse pre-clinical studies expected to be completed by end of July 2019.

Further information on our human development plans will be provided in the near future.